Skip to content
This repository has been archived by the owner on Nov 19, 2024. It is now read-only.

SPL Intent-Use categories for Treatment Modality #184

Open
southalln opened this issue Sep 26, 2023 · 0 comments
Open

SPL Intent-Use categories for Treatment Modality #184

southalln opened this issue Sep 26, 2023 · 0 comments

Comments

@southalln
Copy link
Contributor

FDA's SPL contains information on the intended use of products that corresponds nicely to Treament Modality in Inxight.

https://www.fda.gov/industry/structured-product-labeling-resources/intent-use

I forget how this information comes from FRDB - but one might be able to supplement it with FDA SPL data.

Primary
Substance halts or slows disease progression. Treatment often targets the primary pathology of a disease.
Preventing
Substance is intended to prevent the development of a medical condition.
Palliative
Substance improves the quality of life by alleviating the associated symptoms, without necessarily affecting the underlying pathology.
Secondary
Substance treats adverse effects associated with the treatment of a condition.
Diagnostic
A substance used for diagnostic purposes, including disease detection and monitoring of disease progression.
Inactive Ingredient
An ingredient of a given formulation (most frequently, an excipient) that does not exhibit pharmacological activity. In this case, a condition is only related to such compound via the formulation used to affect (treat or diagnose) this condition.

Sign up for free to subscribe to this conversation on GitHub. Already have an account? Sign in.
Labels
None yet
Projects
None yet
Development

No branches or pull requests

1 participant